Margaret Monson

Retired therapist, $NWBO supporter and investor. I’m not here to provide any financial advice. ExPat who votes from abroad. 💙Democracy Matters! NO DMs 🚫

[Margaret Monson @MonsonVO]

#Portugal 🇵🇹
Anyone looking to purchase a home in Northern Portugal I’m selling my house. It’s just outside of Ponte da Barca in Azias, right next to the Geres National Forest. PM me if you or someone you know is interested in living in Portugal. https://t.co/7aX5RIuzeV

[Margaret Monson @MonsonVO]

Hi Everyone I am taking a much needed break from Social Media. I will not be back on Twitter’s platform. I don’t currently have any plans on a replacement for Twitter. Good luck to all and I wish you all the best! ♥️🙏

[Margaret Monson @MonsonVO]

Congratulations!!! Way to go $NWBO!!! https://t.co/LRevMcFvkd

[The Dapper DO @TheDapperDO]

The Psychology of Selling #NWBO

I am not an expert investor. I am not a financial or technical analyst. I admit that I don’t have much credibility to offer when it comes to investing, and I wouldn’t encourage anyone to cling to my personal opinion or strategy.

But I AM a Physician that knows medicine. And what I know is that DC Vax is simply extraordinary. I know that we are on the cusp of unleashing a therapy to the world that sounds like something written in science fiction, a treatment that I would doubt could even exist if I had heard about it 20 years ago… and yet, here we are.

Allegedly, some nefarious characters have driven its “value” to a mere $00.20, and there seem to be a plethora of supposed non-invested parties that skirt the edge of an opinion, issue vague, non-descriptive statements about its efficacy or management, and criticize the medicine or the company trying to bring it to the public. I would bet my last dollar that those same people would give their own right arms to have if they or their family members were ever diagnosed with cancer.

I believe it is worth a whole lot more than that.

I believe that we are starting to see things heating up. They say a watched pot never boils, but we all know that given enough time, it does. And I believe it’s going to boil fast and overflow.

“They” want you to believe that seeing the share price go to $1.00 is a miracle, that $2.00 is TEN times what the price is now! What a bargain! I think “they” believe we are gullible fools, and there are plenty of non-invested parties apparently trying to protect you from how you spend your own money.

What does it mean to hold on? It means that you stop and think about what this treatment is truly worth to the millions of people whose lives may soon depend on it, whose families are already scraping together every penny they can to try to obtain it for their loved ones, and whose progress was almost destroyed (allegedly) by corporate greed and avarice.

Of course, this is all just my opinion. It is definitely not investment advice. But I believe in the medicine, and I believe that selling anything soon is playing right into the hands that tried to take it all away from the patients that deserve it.

[Justin Keister MS DABR @justinkeister5]

$NWBO #DCVAX involves some of the most complex, groundbreaking science and biologic engineering known to man. In hindsight, first approval was never going to be easy.

Nothing worth it ever is.

[NWBOstacks @EatYerShorts]

Why would #NWBO drop serious cash on a dedicated leukapheresis clinic in London—equipment already delivered, opening June—if they were secretly terrified of MHRA rejection?

FUDtrolls: "Dead company!"

Management: "Hold my buildout." 😂

[Margaret Monson @MonsonVO]

@Investisco @MHRAgovuk And for me to add more shares today at .104!

[Peter Davis @peter_brit]

#dcvax $nwbo #gbm

Geminii AI Analysis of significant updates and relevance:

The inspection report for Advent Bioservices Ltd (Licence 22694), with the final report issued in February 2026, contains several significant updates following their acquisition by Northwest Biotherapeutics and the transition of their primary operations.

The most critical changes identified in the report and related regulatory filings include:

1. License Activity and Site Consolidation
The most significant development is the closure of operations at the London GMP facility and the reallocation of all licensed activities to the Sawston, UK facility.

New Primary Site: The HTA license now focuses on the Sawston facility (near Cambridge), which was designed as a state-of-the-art facility for multiproduct Good Manufacturing Practice (GMP) production.

Capacity Scale-up: The report reflects the transition from a Contract Development and Manufacturing Organisation (CDMO) model to a fully integrated platform supporting the scale-up of Northwest Biotherapeutics' DCVax® personalized immune therapies.

2. Regulatory Suitability and "New" License Status
Although the license number (22694) remains the same, the "newness" refers to the HTA's assessment of the establishment under its new corporate structure and at the expanded Sawston site.

Suitability Confirmed: The HTA found the Designated Individual (DI) and the Licence Holder (LH) to be suitable in accordance with legislative requirements.

Activities Authorized: The establishment is licensed for:
Procurement
Import
Export
Testing
Storage of relevant material for use in Human Application.

3. Inspection Findings (Finalized Feb 2026)

The February 2026 final report confirms that the establishment met the majority of HTA standards, but highlights specific areas of focus during the transition:

Governance and Quality Systems (GQ): The HTA verified that documented policies and procedures are now aligned with the Sawston site's workflows.

Traceability (TR): As the site is now handling significant volumes of autologous tumor tissue and PBMCs (Peripheral Blood Mononuclear Cells), the HTA emphasized the maintenance of the "vein-to-vein" traceability chain.

Premises, Facilities, and Equipment (PFE): The inspection focused on the newly validated cleanroom suites and the environmental monitoring systems (EMS) at the Sawston site to ensure they meet HTA's high-grade sterility requirements.

4. Governance Changes
The report notes updates to key personnel following the acquisition:

Designated Individual (DI): The DI is responsible for overseeing compliance. The current DI listed is Arjmand Aziz.

Corporate Integration: The license holder now operates as a wholly-owned subsidiary of Northwest Biotherapeutics, facilitating streamlined interactions with clinical sites for the distribution of cell therapy products.

This report essentially serves as the "green light" for the establishment to operate at full capacity under its new integrated corporate structure, specifically supporting the commercial-scale production of personalized cancer vaccines.

[Margaret Monson @MonsonVO]

@nipomo357 Me too! Congratulations.

[Margaret Monson @MonsonVO]

@KenjaevRasul IMO $NWBO isn’t looking to be acquired. They have an immunotherapy platform and have franchise agreements in place. These will be announced after certain milestones are met (Linda Powers discussion 2 ASMs ago). Linda mentioned this last ASM about regional franchise agreements.

[Margaret Monson @MonsonVO]

@exosome Me too!

[Margaret Monson @MonsonVO]

@BillB95488845 @TerryRo84010346 @johnnydeeze